

Jill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9740556/publications.pdf>

Version: 2024-02-01

32
papers

1,053
citations

430442

18
h-index

454577

30
g-index

32
all docs

32
docs citations

32
times ranked

1534
citing authors

#	ARTICLE	IF	CITATIONS
1	Sex and Gender Differences in Lung Cancer and Chronic Obstructive Lung Disease. <i>Endocrinology</i> , 2022, 163, .	1.4	21
2	Targeting the ER ¹² /HER Oncogenic Network in KRAS Mutant Lung Cancer Modulates the Tumor Microenvironment and Is Synergistic with Sequential Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 81.	1.8	6
3	Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting. <i>Journal of Cancer Prevention</i> , 2021, 26, 71-82.	0.8	4
4	Inhibiting Pathways Predicted From a Steroid Hormone Gene Signature Yields Synergistic Antitumor Effects in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 62-79.	0.5	11
5	Prevention of Tobacco Carcinogen-Induced Lung Tumor Development by a Novel STAT3 Decoy Inhibitor. <i>Cancer Prevention Research</i> , 2020, 13, 735-746.	0.7	4
6	Lung Adenocarcinoma Syndecan-2 Potentiates Cell Invasiveness. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2019, 60, 659-666.	1.4	20
7	Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 399-412.	0.5	25
8	Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer. <i>Cancers</i> , 2018, 10, 280.	1.7	52
9	STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non-“Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1917-1926.	1.9	30
10	KRAS and TP53 mutations in bronchoscopy samples from former lung cancer patients. <i>Molecular Carcinogenesis</i> , 2017, 56, 381-388.	1.3	25
11	Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-“small cell lung cancer. <i>Cancer</i> , 2017, 123, 2936-2944.	2.0	36
12	Lung Endothelial MicroRNA-1 Regulates Tumor Growth and Angiogenesis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1443-1455.	2.5	31
13	Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1512-1523.	0.5	6
14	Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 24063-24076.	0.8	26
15	Gene methylation biomarkers in sputum as a classifier for lung cancer risk. <i>Oncotarget</i> , 2017, 8, 63978-63985.	0.8	19
16	ATM protein is deficient in over 40% of lung adenocarcinomas. <i>Oncotarget</i> , 2016, 7, 57714-57725.	0.8	35
17	Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome. <i>Neoplasia</i> , 2015, 17, 817-825.	2.3	29
18	Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma. <i>BMC Cancer</i> , 2015, 15, 649.	1.1	11

#	ARTICLE	IF	CITATIONS
19	Smoking Out Reproductive Hormone Actions in Lung Cancer. <i>Molecular Cancer Research</i> , 2014, 12, 24-31.	1.5	28
20	Erlotinib, Erlotinib+Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3289-3298.	3.2	48
21	Estrogenic Steroid Hormones in Lung Cancer. <i>Seminars in Oncology</i> , 2014, 41, 5-16.	0.8	95
22	Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens. <i>Carcinogenesis</i> , 2012, 33, 2181-2189.	1.3	48
23	Combining the Multitargeted Tyrosine Kinase Inhibitor Vandetanib with the Antiestrogen Fulvestrant Enhances Its Antitumor Effect in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 485-495.	0.5	53
24	HGF Airway Over-expression Leads to Enhanced Pulmonary Vascularization without Induction of VEGF. <i>Current Angiogenesis</i> , 2012, 1, 52-63.	0.1	0
25	Combined Analysis of Estrogen Receptor β -1 and Progesterone Receptor Expression Identifies Lung Cancer Patients with Poor Outcome. <i>Clinical Cancer Research</i> , 2011, 17, 154-164.	3.2	139
26	Early Changes in Pulmonary Gene Expression following Tobacco Exposure Shed Light on the Role of Estrogen Metabolism in Lung Carcinogenesis. <i>Cancer Prevention Research</i> , 2010, 3, 692-695.	0.7	12
27	Estrogen Receptor Signaling in Lung Cancer. <i>Seminars in Oncology</i> , 2009, 36, 524-531.	0.8	112
28	Signaling Pathways Involved in Cyclooxygenase-2 Induction by Hepatocyte Growth Factor in Non-Small-Cell Lung Cancer. <i>Molecular Pharmacology</i> , 2007, 72, 769-779.	1.0	37
29	Polymorphisms in DNA repair genes XPD and XRCC1 and p53 mutations in lung carcinomas of never-smokers. <i>Molecular Carcinogenesis</i> , 2006, 45, 828-832.	1.3	16
30	Detection of low-fraction K-ras mutations in primary lung tumors using a sensitive method. , 1997, 74, 162-170.		17
31	Effects of bombesin and gastrin-releasing peptide on human bronchial epithelial cells from a series of donors: Individual variation and modulation by bombesin analogs. <i>The Anatomical Record</i> , 1993, 236, 241-247.	2.3	42
32	Culture of primary lung tumors using medium conditioned by a lung carcinoma cell line. <i>Journal of Cellular Biochemistry</i> , 1989, 41, 91-95.	1.2	15